Tandem Diabetes Care has expanded the compatibility of its t:slim X2 insulin pump to include Abbott’s FreeStyle Libre 3 Plus sensor in the United States. The update is preloaded on new shipments and available free of charge for eligible existing pumps via remote update.
The FreeStyle Libre 3 Plus sensor is the world’s smallest continuous glucose monitor, transmitting readings every minute and offering a 15‑day wear time. The integration allows Tandem’s Control‑IQ+ algorithm to use the sensor data to adjust insulin delivery every five minutes, delivering automatic correction boluses based on predicted glucose values.
The launch follows Tandem’s earlier integration of the FreeStyle Libre 2 Plus sensor in January 2024 and signals the company’s intent to broaden its sensor ecosystem beyond Dexcom. The partnership also paves the way for future pairing with Abbott’s dual glucose‑ketone sensor currently under development.
In its Q3 2024 earnings, Tandem reported worldwide GAAP sales of $244 million, up 31% from $194 million in Q3 2023, with U.S. sales rising to $171 million from $138 million. Management highlighted strong demand for automated insulin delivery systems and noted that growth may slow in 2025 due to new product introductions and competitive dynamics.
The expansion positions Tandem to capture a larger share of the U.S. insulin‑pump market, which is projected to grow as diabetes prevalence rises and technology advances. By offering compatibility with Abbott’s CGM platform, Tandem provides users with greater choice and enhances the overall user experience.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.